Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787588 | 0.82 | MAPT (0.47) | MAPTGAAHDAC6MEN1KMT2A | |
| SCHEMBL1789819 | 0.81 | ROCK2 (0.49) | MAPTHDAC6HTTPRMT5WDR77 | |
| SCHEMBL1787963 | 0.80 | HSD17B13 (0.39) | MAPTHDAC6KMT2AHTTLMNA | |
| SCHEMBL1788808 | 0.79 | RAB9A (0.48) | MAPTHDAC6LMNAALDH1A1TP53 | |
| SCHEMBL1789087 | 0.79 | TSHR (0.53) | MAPTHDAC6KMT2ARAB9A | |
| SCHEMBL1791547 | 0.77 | HDAC6 (0.39) | MAPTGAAHDAC6HDAC1NPC1 | |
| SCHEMBL1788606 | 0.77 | NAMPT (0.48) | MAPTHDAC6MEN1KMT2AALDH1A1 | |
| SCHEMBL1787944 | 0.77 | MAPT (0.41) | MAPTHDAC6KMT2AALDH1A1TP53 | |
| SCHEMBL1790046 | 0.77 | KDM4E (0.52) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL1787706 | 0.77 | HDAC6 (0.43) | HDAC6KMT2AHTTPRMT5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | MAPT 3598/4885GAA 4339/4885HDAC6 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.